ConductScience.org, home

Library / Genes

ITGAV: integrin subunit alpha V

1 protein, 64 patents, 15 drugs, 68 trials, 5,057 NIH grants and 11,061 papers.

Gene 7

Its symbol and name are HGNC's, unless HGNC and NCBI Gene contradict each other.

FieldValueSource
SymbolITGAVHGNC
Nameintegrin subunit alpha VHGNC
NCBI Gene ID3685NCBI Gene
HGNC IDHGNC:6150HGNC
EnsemblENSG00000138448NCBI Gene
AliasesCD51, IDNDC, MSK8, VNRA, VTNRNCBI Gene
Typeprotein-codingNCBI Gene

Proteins 1

Reviewed human proteins whose Swiss-Prot entry states the gene.

UniProt entryProteinLengthStructuresGene stated inSource
P06756Integrin alpha-V1,04859Ensembl, GeneID, HGNCUniProt

Patents 64

Patents whose sequence listing holds the protein exactly: the same sequence, by SHA-256, length and CRC-64. A sequence a patent lists is not always one it claims.

PublicationPublishedSEQ ID NOProteinSource
JP 2026088136 A2026-05-28342P06756Espacenet
JP 2026082951 A2026-05-1927P06756Espacenet
EP 4684799 A22026-01-28342P06756Espacenet
WO 2025259600 A22025-12-1820P06756Espacenet
WO 2025253854 A2025-12-111P06756Espacenet
EP 4650780 A22025-11-191839P06756Espacenet
EP 4641201 A22025-10-291421P06756Espacenet
EP 4631545 A12025-10-151P06756Espacenet
WO 2025194019 A12025-09-185P06756Espacenet
JP 2025529142 A2025-09-042146P06756Espacenet

Drugs 15

Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.

DrugChEMBL IDMechanismActionSource
ABCIXIMABCHEMBL1201584Integrin alpha-V/beta-3 inhibitorINHIBITORChEMBL
ABITUZUMABCHEMBL2109621Integrin alpha-V/beta-1 inhibitorINHIBITORChEMBL
ABITUZUMABCHEMBL2109621Integrin alpha-V/beta-3 inhibitorINHIBITORChEMBL
ABITUZUMABCHEMBL2109621Integrin alpha-V/beta-5 inhibitorINHIBITORChEMBL
ABITUZUMABCHEMBL2109621Integrin alpha-V/beta-6 inhibitorINHIBITORChEMBL
ABITUZUMABCHEMBL2109621Integrin alpha-V/beta-8 inhibitorINHIBITORChEMBL
ATN-161CHEMBL4297456Integrin alpha-V/beta-3 antagonistANTAGONISTChEMBL
CILENGITIDECHEMBL429876Integrin alpha-V/beta-3 antagonistANTAGONISTChEMBL
CILENGITIDECHEMBL429876Integrin alpha-V/beta-5 antagonistANTAGONISTChEMBL
ETARACIZUMABCHEMBL5314357Integrin alpha-V/beta-3 antagonistANTAGONISTChEMBL

Trials 68

Trials of those drugs. A trial joins the gene only through a drug that acts on it.

TrialDrugPhaseResults first postedSource
NCT05415150ABCIXIMABPHASE1/PHASE2ClinicalTrials.gov
NCT03688230ABITUZUMABPHASE2ClinicalTrials.gov
NCT03573505STX-100PHASE22020-11-20ClinicalTrials.gov
NCT03087539ABCIXIMABPHASE2ClinicalTrials.gov
NCT02745145ABITUZUMABPHASE22019-06-18ClinicalTrials.gov
NCT02181985ABCIXIMABPHASE3ClinicalTrials.gov
NCT02105870ABCIXIMABClinicalTrials.gov
NCT01932554ABCIXIMABPHASE2ClinicalTrials.gov
NCT01782976CILENGITIDEPHASE2ClinicalTrials.gov
NCT01558687CILENGITIDEPHASE1ClinicalTrials.gov

NIH grants 5057

NIH projects whose papers are about the gene, through NIH's grant-paper links.

ProjectTitleIts papers about the geneNewest fiscal yearSource
P30CA014520UW Comprehensive Cancer Center Support372,025NIH's project files
P30CA016672Cancer Center Support Grant292,025NIH's project files
P30CA093373Cancer Center Support Grant P30272,025NIH's project files
P30CA008748Cancer Center Support Grant212,025NIH's project files
P30CA091842Cancer Center Support Grant102,025NIH's project files
P30EY016665Core Grant for Vision Research102,025NIH's project files
P30CA012197Cancer Center Support Grant92,025NIH's project files
P30CA016042Cancer Center Support Grant92,025NIH's project files
P30CA047904Cancer Center Support Grant92,025NIH's project files
P30CA068485Cancer Center Support Grant92,025NIH's project files

Papers 11061

Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.

PMIDFound bySource
42812828PubTator, text miningPubMed
42811985PubTator, text miningPubMed
42798452PubTator, text miningPubMed
42779461PubTator, text miningPubMed
42765067PubTator, text miningPubMed
42757471PubTator, text miningPubMed
42754734PubTator, text miningPubMed
42714955PubTator, text miningPubMed
42705592PubTator, text miningPubMed
42699801PubTator, text miningPubMed

The same record as JSON

Release gene-search-2026-11-11-0.1.0

ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

ChEMBL, through Open Targets: CC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence

ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

EMBL-EBI's patent proteins: EMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use

GenBank's patent files: GenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/

HGNC: CC0: https://www.genenames.org/about/license/

NCBI Gene: None named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/

NIH's project files and grant-paper links: Public domain (NIH RePORTER)

Open Targets: CC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence

PubTator 3: Public domain

UniProt: CC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license